Generic Name and Formulations:
C1 inhibitor (human) 500 Units/vial; lyophilized pwd for IV infusion after reconstitution; preservative-free.
Shire US, Inc.
Routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE).
Give by IV infusion at a rate of 1mL/min (10mins). 1000 Units every 3–4 days.
Contains human plasma; monitor for possible infection transmission. Have epinephrine available to treat hypersensitivity reactions. Monitor patients with known risk factors for thrombotic events. Labor & delivery. Pregnancy (Cat.C). Nursing mothers.
Upper respiratory tract infection, sinusitis, rash, headache; thrombotic events, hypersensitivity reactions (may be severe); discontinue if occurs.
To report infections that may have been transmitted by Cinryze, call CinryzeSolutions at (877) 945-1000.
Join MIMS Learning now to manage all your CPD and notes in one place!
Already a MIMS Learning member?Sign In Now »
This red flags article explains signs and symptoms of potentially serious pathology in patients presenting...
This article by Dr Tillmann Jacobi covers the possible red flag symptoms to consider when a patient...
Dr Suneeta Kochhar provides an overview of red flag symptoms in patients presenting with headaches...
In this article, Dr David Brass and Dr Neil Rajan discuss the risk factors for BCC, making the diagnosis...
This article by Dr Rajiv Sankaranarayanan covers the diagnosis and management of cardiomyopathy. Key...
Dr Benjamin Simpson provides an in-depth overview of Parkinson’s disease, including information on risk...